Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02267603
Title Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Merkel cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.